Key result
Current evidence for intravenous vasodilators and the potential of novel therapies in development are reviewed for the management of acute heart failure.
This review examines the current evidence for intravenous vasodilators in acute heart failure and discusses novel therapies in development.
Highlights gaps in IV vasodilator evidence for acute HF; leaves open the role of novel therapies.
Acute heart failure is a major cause of emergency hospital admission, with significant impact on health resources and patient outcomes. With no new treatments for over 20 years, the advent of new innovative therapies may facilitate a radical change in our approach to such patients. In this article, we examine the current evidence for the use of current intravenous vasodilators in AHF management, and review the potential of novel therapies currently in development.
No takes yet. Share an insight, caveat, or question.
Piper et al. (2014) conducted a review in Acute heart failure. Intravenous vasodilators was evaluated. Current evidence for intravenous vasodilators and the potential of novel therapies in development are reviewed for the management of acute heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: